Clinical Presentation, Diagnosis and Prognosis of Pregnancy-Associated Breast Cancer

2020 ◽  
pp. 87-93
Author(s):  
James Sun ◽  
Marie Catherine Lee
Keyword(s):  
Breast Cancer ◽  
Clinical Presentation ◽  
Diagnosis And Prognosis

scholarly journals Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer

2021 ◽  
Vol 22 (2) ◽  
pp. 636
Author(s):  
Hsing-Ju Wu ◽  
Pei-Yi Chu
Keyword(s):  
Breast Cancer ◽  
Normal Breast ◽  
New Drugs ◽  
Cancer Type ◽  
Luminal A ◽  
Luminal B ◽  
Therapeutic Implications ◽  
Whole Cells ◽  
Diagnosis And Prognosis ◽  
Novel Biomarkers

Breast cancer is the most commonly diagnosed cancer type and the leading cause of cancer-related mortality in women worldwide. Breast cancer is fairly heterogeneous and reveals six molecular subtypes: luminal A, luminal B, HER2+, basal-like subtype (ER−, PR−, and HER2−), normal breast-like, and claudin-low. Breast cancer screening and early diagnosis play critical roles in improving therapeutic outcomes and prognosis. Mammography is currently the main commercially available detection method for breast cancer; however, it has numerous limitations. Therefore, reliable noninvasive diagnostic and prognostic biomarkers are required. Biomarkers used in cancer range from macromolecules, such as DNA, RNA, and proteins, to whole cells. Biomarkers for cancer risk, diagnosis, proliferation, metastasis, drug resistance, and prognosis have been identified in breast cancer. In addition, there is currently a greater demand for personalized or precise treatments; moreover, the identification of novel biomarkers to further the development of new drugs is urgently needed. In this review, we summarize and focus on the recent discoveries of promising macromolecules and cell-based biomarkers for the diagnosis and prognosis of breast cancer and provide implications for therapeutic strategies.

Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer?

Cancer ◽  
2007 ◽  
Vol 109 (10) ◽  
pp. 2093-2099 ◽  
Author(s):  
A. Tyler Watlington ◽  
Tim Byers ◽  
Judy Mouchawar ◽  
Angela Sauaia ◽  
Jenn Ellis
Keyword(s):  
Breast Cancer ◽  
White Women ◽  
Clinical Presentation ◽  
Hispanic White

Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies

2021 ◽  
Author(s):  
Dan Li ◽  
Wenjia Lai ◽  
Di Fan ◽  
Qiaojun Fang
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Extracellular Vesicles ◽  
Liquid Biopsy ◽  
Breast Cancer Diagnosis ◽  
Extracellular Vesicle ◽  
Detection Methods ◽  
Protein Markers ◽  
Liquid Biopsies ◽  
Diagnosis And Prognosis

Breast cancer is the most common malignant disease in women worldwide. Early diagnosis and treatment can greatly improve the management of breast cancer. Liquid biopsies are becoming convenient detection methods for diagnosing and monitoring breast cancer due to their non-invasiveness and ability to provide real-time feedback. A range of liquid biopsy markers, including circulating tumor proteins, circulating tumor cells, and circulating tumor nucleic acids, have been implemented for breast cancer diagnosis and prognosis, with each having its own advantages and limitations. Circulating extracellular vesicles are messengers of intercellular communication that are packed with information from mother cells and are found in a wide variety of bodily fluids; thus, they are emerging as ideal candidates for liquid biopsy biomarkers. In this review, we summarize extracellular vesicle protein markers that can be potentially used for the early diagnosis and prognosis of breast cancer or determining its specific subtypes.

scholarly journals VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patients

2021 ◽  
Author(s):  
Chun-Yu Liu ◽  
Chi-Cheng Huang ◽  
Yi-Fang Tsai ◽  
Ta-Chung Chao ◽  
Pei-Ju Lien ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Recurrence ◽  
Cell Receptor ◽  
Breast Cancer Patients ◽  
Genetic Profiling ◽  
Treatment Regimens ◽  
Diagnosis And Prognosis ◽  
Receptor Repertoire ◽  
Cell Receptor Repertoire ◽  
Selection Of

Heterogeneity in breast cancer leads to diverse morphological features and different clinical outcomes. There are inherent differences in breast cancer between the populations in Asia and in western countries. The use of immune-based treatment in breast cancer is currently in the developmental stage. The VGH-TAYLOR study is designed to understand the genetic profiling of different subtypes of breast cancer in Taiwan and define the molecular risk factors for breast cancer recurrence. The T-cell receptor repertoire and the potential effects of immunotherapy in breast cancer subjects is evaluated. The favorable biomarkers for early detection of tumor recurrence, diagnosis and prognosis may provide clues for the selection of individualized treatment regimens and improvement in breast cancer therapy.

Review of Pineal Anlage Tumor With Divergent Histology

2006 ◽  
Vol 130 (8) ◽  
pp. 1233-1235
Author(s):  
Stephen Berns ◽  
Gary Pearl
Keyword(s):  
Clinical Presentation ◽  
World Health ◽  
Pineal Tumor ◽  
Rare Tumor ◽  
World Health Organization Classification ◽  
Nervous System Tumors ◽  
Diagnosis And Prognosis ◽  
Endodermal Differentiation ◽  
Health Organization

Abstract Pineal anlage tumor is an extremely rare tumor that is not listed in the 2000 World Health Organization Classification of nervous system tumors. It has been defined as a primary pineal tumor with both neuroepithelial and ectomesenchymal differentiation and without endodermal differentiation. We review the literature on this tumor, including the clinical presentation, gross pathology, histopathology, immunohistochemistry, differential diagnosis, and prognosis.

Sign in / Sign up

Export Citation Format

Share Document